For the quarter ending 2026-03-31, LGNYZ made $51,722K in revenue. -$13,345K in net income. Net profit margin of -25.80%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Total revenues and income | 51,722 | -78,296* | 115,461 | |
| Cost of captisol | 3,273 | 3,146* | 3,801 | |
| Amortization of intangibles | 8,097 | 8,417* | 8,097 | |
| Research and development | 2,148 | 18,125* | 21,019 | |
| General and administrative | 20,836 | 7,111* | 28,446 | |
| Financial royalty assets impairment | - | 6,197* | 0 | |
| Fair value adjustments to partner program derivatives | 0 | -2,499* | 833 | |
| Total operating costs and expenses | 34,354 | 45,495* | 60,530 | |
| Gain on sale of pelican | - | 0* | - | |
| Operating income (gain) | 17,368 | -123,791* | 54,931 | |
| Loss (gain) from short-term investments | 3,869 | -4,961* | 7,798 | |
| Gain from change in fair value of equity-method investments and other investments | -49,229 | -136,991* | 75,887 | |
| Interest income | 6,655 | 2,037* | 3,874 | |
| Interest expense | 1,747 | 1,985* | 910 | |
| Other non-operating expense, net | -1,175 | 1,240* | -443 | |
| Total non-operating expenses, net | -41,627 | -140,660* | 86,206 | |
| Gain before income taxes | -24,259 | -264,451* | 141,137 | |
| Income tax benefit | -10,914 | -37,085* | 23,864 | |
| Net income (loss) from continuing operations | - | -227,366 | - | |
| Net gain | -13,345 | -227,366 | 117,273 | |
| Basic EPS | -0.67 | -11.905 | 5.99 | |
| Diluted EPS | -0.67 | -11.392 | 5.68 | |
| Basic Average Shares | 19,883,000 | 19,098,000 | 19,578,000 | |
| Diluted Average Shares | 19,883,000 | 19,959,000 | 20,629,000 | |
LIGAND PHARMACEUTICALS INC (LGNYZ)
LIGAND PHARMACEUTICALS INC (LGNYZ)